PT
Paul Tudor Jones II (Tudor Investment) disclosed new in Crinetics Pharmaceuticals Inc - US
Paul Tudor Jones II (Tudor Investment) filed a 13F change in Crinetics Pharmaceuticals Inc - US (22663K107) on 2026-05-15, covering period end 2026-03-31.
Action
New
Capital
$1,671,483 reported value
Institutional 13F Signals1 evidence source
Why it matters
This signal is anchored to the SEC filing date while retaining the underlying 13F period end.